3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Glioma
12
Brain Neoplasms
8
Melanoma
7
Neurofibromatosis 1
5
Astrocytoma
5
Neurofibroma, Plexiform
4
Neoplasms
4
Glioblastoma
4
Oligodendroglioma
3
Multiple Myeloma
3
Histiocytosis, Langerhans-Cell
3
Thyroid Carcinoma, Anaplastic
2
Ovarian Neoplasms
2
Neurocytoma
2
Neuroblastoma
2
Meningioma
2
Lung Neoplasms
2
Leukemia, Myelomonocytic, Juvenile
2
Hematologic Neoplasms
2
Ganglioneuroma
2
Ganglioglioma
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Rhabdoid Tumor
1
Interventions
selpercatinib
2
alectinib
2
tucatinib
1
trametinib
1
pamiparib
1
glutathione pegylated liposomal doxorubicin
1
entrectinib
1
elacestrant
1
dabrafenib
1
cobimetinib
1
capmatinib
1
abemaciclib
1
Vemurafenib
1
Trastuzumab
1
Radiation
1
RAD1901
1
Pemetrexed
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
trametinib
×
CNS
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled